Benign Prostatic Hyperplasia (The Aging Prostate)

Medina, Juan José Martínez; Parra, Raul O.; Moore, Robert G.

doi:10.1016/s0025-7125(05)70159-0

Cited by 58 publications

(48 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33 It has been suggested that a1-adrenergic receptors are upregulated in patients with LUTS associated with BPH, resulting in increased smooth muscle tone in the prostatic capsule and bladder neck. 34 Rat models have demonstrated an effect on prostatic growth and differentiation through manipulation of autonomic activity. 35 Not only can changes at the level of adrenergic receptor expression and circulating sympathetic neurotransmitters explain a link between ED and LUTS, but also changes at the level of the myosinactin filament interaction leading to smooth muscle hypercontractility have further been described in both diseases.…”

Section: Luts and Ed: Pathophysiological Correlationsmentioning

confidence: 99%

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

2011

View full text Add to dashboard Cite

There is strong evidence from multiple epidemological studies that lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are correlated, independent of age or comorbidities as diabetes or hypertension. Although a direct causal relationship is not established yet, four pathophysio logical mechanisms can explain the relationship. These include alteration in nitric oxide bioavailability, a1-adrenergic receptor hyperactivity, pelvic atherosclerosis and sex hormones. This association has different clinical implications on the management of both disorders. Men seeking care for one condition should always be screened for complaints of the other condition. Sexual function should be assessed and discussed with the patient when choosing the appropriate management strategy for LUTS, as well as when evaluating the patient's response to treatment. Multiple large clinical trials have shown an improvement in LUTS after phosphodiesterase-5 (PDE5)-inhibitor treatment. PDE5 inhibitors show promise as a future treatment for LUTS, either in conjunction with existing therapies or as a primary treatment. There may be a potential therapeutic role for testosterone in LUTS treatment in cases of testosterone deficiency that needs to be investigated. Much further investigation is required, but it is evident that the association between LUTS and ED is fundamental for future therapies and possible preventative strategies.

show abstract

Section: Luts and Ed: Pathophysiological Correlationsmentioning

confidence: 99%

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

2011

View full text Add to dashboard Cite

show abstract

“…The conditions leading to lower urinary tract symptoms (LUTS) are among the most prevalent diseases of elderly males, with potential impairment of quality of life (QoL) (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). Among elderly men, benign prostatic enlargement (BPE) is the main cause of LUTS, which can be evaluated by the International Prostate Symptom Score (IPSS) (1)(2)(3)12).…”

Section: Introductionmentioning

confidence: 99%

“…Among elderly men, benign prostatic enlargement (BPE) is the main cause of LUTS, which can be evaluated by the International Prostate Symptom Score (IPSS) (1)(2)(3)12). Among elderly men, benign prostatic enlargement (BPE) is the main cause of LUTS.…”

Section: Introductionmentioning

confidence: 99%

Elderly men's quality of life and lower urinary tract symptoms: an intricate relationship

et al. 2011

View full text Add to dashboard Cite

Purpose:To evaluate the impact of lower urinary tract symptoms (LUTS) on the quality of life (QoL) in a group of elderly men. Materials and Methods:Observational clinical study contained 200 men recruited between March-September 2008 in the community and Urology and Geriatrics ambulatories. The data collected included health and sociodemographic conditions; the International Prostate Symptom Score (IPSS); an anxiety/depression inventory; the World Health Organization Quality of Life -Bref and -Old questionnaires (WHOQoL). Participants were classified according to IPSS: Group I (moderate/severe symptoms) and Group II (absence/mild symptoms) and 100 men were included in each group. Results: The groups were statistically similar in sociodemographic, morbidity, and anxiety/depression scores. Both QoL scales showed significant lower median scores in group I in all parameters, except the global subjective self-evaluation of QoL. The domains social and environmental relations presented the most significative differences (p < 0.0005) in both questionnaires, and final mean WHOQoL-Old score was lower in group I (p < 0.0005). Conclusions: For elderly men, moderate to severe LUTS do significantly impact almost all parameters of QoL proposed by the WHO, especially social and environmental relations.

show abstract

“…1 Dynamic manifestations of LUTS include increased frequency of urination, nocturia, and urgency, symptoms that are linked to an increase in smooth-muscle tone, predominantly in the capsule of the prostate and the bladder neck, resulting from stimulation of a 1 -adrenergic receptors in these tissues. 2 Pharmacologic blockade of a 1 -adrenergic receptors relaxes the smooth muscle of the prostate and bladder neck and improves symptoms in many patients with BPH. For this reason, a 1 -blockers are now considered first-line agents for the management of LUTS due to BPH.…”

Section: Introductionmentioning

confidence: 99%

Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate

Roehrborn

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Treatment with a 1 -adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15 mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4 ml from baseline in placebo patients but decreased by À0.25 ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.

show abstract

Benign Prostatic Hyperplasia (The Aging Prostate)

Cited by 58 publications

References 29 publications

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management

Elderly men's quality of life and lower urinary tract symptoms: an intricate relationship

Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate

Contact Info

Product

Resources

About